Spin-off closed
Sensodyne and 7 other brands separation from GSK (2022)
Sensodyne and 7 other brands was separated from GSK as Haleon on 18 July 2022.[1]
GSK demerged its consumer healthcare business as Haleon, listing it in London and New York in July 2022. The business already contained Pfizer's consumer health portfolio, contributed to a joint venture in 2019, which is how Advil and Centrum came to sit alongside Sensodyne and Panadol.
Deal facts
- Announced
- Closed
- Value
- Not recorded
- New owner
- Haleon
- Former parent
- GSK
- Assets
- Sensodyne, Panadol, Voltaren, Centrum, Advil, Polident, Otrivin, Parodontax
- Regulatory review
- None recorded
Ownership changes recorded from this deal
| Owner | Owned | Relationship | Stake | From | To |
|---|---|---|---|---|---|
| GSK | Sensodyne | owns | 100% | 2000-12-27 | 2022-07-18 |
| GSK | Panadol | owns | 100% | 2000-12-27 | 2022-07-18 |
| GSK | Voltaren | owns | 100% | 2015-03-02 | 2022-07-18 |
| GSK | Centrum | owns | 100% | 2019-08-01 | 2022-07-18 |
| GSK | Advil | owns | 100% | 2019-08-01 | 2022-07-18 |
| GSK | Polident | owns | 100% | 2000-12-27 | 2022-07-18 |
| GSK | Otrivin | owns | 100% | 2015-03-02 | 2022-07-18 |
| GSK | Parodontax | owns | 100% | 2000-12-27 | 2022-07-18 |
| Haleon | Sensodyne | owns | 100% | 2022-07-18 | present |
| Haleon | Panadol | owns | 100% | 2022-07-18 | present |
| Haleon | Voltaren | owns | 100% | 2022-07-18 | present |
| Haleon | Centrum | owns | 100% | 2022-07-18 | present |
| Haleon | Advil | owns | 100% | 2022-07-18 | present |
| Haleon | Polident | owns | 100% | 2022-07-18 | present |
| Haleon | Otrivin | owns | 100% | 2022-07-18 | present |
| Haleon | Parodontax | owns | 100% | 2022-07-18 | present |
Who owns these brands today?
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Haleon plc Annual Report — SEC EDGAR, SEC Form 20-F; retrieved 6 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.